Remove Development Remove FDA Approval Remove Protein
article thumbnail

GPCR-targeting drugs: A renewed focus on a ubiquitous group of proteins

Bio Pharma Dive

As many as a third of FDA-approved drugs target GPCRs in some fashion, with uses ranging from treating cancer to pain. But biotech startups say there is still room to develop more.

Protein 360
article thumbnail

Symvess: Humacyte’s FDA-Approved Bioengineered Solution for Vascular Trauma

XTalks

Symvess is a one-time, single-use, acellular tissue-engineered vessel (ATEV) composed of human extracellular matrix proteins. While Symvess focuses on arterial repair, other developments like AQUACEL Ag+ Extra, Molnlycke Health Cares wound management technologies and Traumagel are advancing care in related areas.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA approves Sanofi’s long-lasting hemophilia drug

Bio Pharma Dive

Sanofi and its development partner, Sobi, claim the drug’s once-a-week dosing, and its effect on blood-clotting protein levels, will help it compete in the crowded market for hemophilia A treatments.

article thumbnail

Alyftrek: Vertex Expands Cystic Fibrosis Treatment with Triple-Action Combo

XTalks

This approval marks a significant milestone for Vertex Pharmaceuticals, making Alyftrek their fifth CFTR modulator to secure FDA approval, offering hope to an expanded group of CF patients. CF is a progressive genetic disease caused by defective CFTR proteins, which are crucial for regulating salt and water movement in cells.

article thumbnail

US FDA approves Kamada’s application to manufacture Cytogam

Pharmaceutical Technology

The US Food and Drug Administration (FDA) approved Kamada’s application to manufacture Cytogam (cytomegalovirus immune globulin intravenous [human]) at its facility located in Beit Kama, Israel. The regulatory approval represents the completion of the Cytogam technology transfer process from CSL Behring, its previous manufacturer.

article thumbnail

Romvimza (Vimseltinib) for TGCT: FDA Approves Oral CSF1-Targeted Drug

XTalks

Deciphera leverages its proprietary switch-control kinase inhibitor platform targeting kinase activation to develop orally administered drug candidates, reflecting its commitment to innovative treatments for conditions with limited therapeutic options. TGCT is a rare, non-cancerous tumor that develops inside or near joints.

article thumbnail

US FDA approves AbbVie-Janssen’s Imbruvica for cGVHD in children

Pharmaceutical Technology

An oral, once-daily therapy, Imbruvica is a Bruton’s tyrosine kinase (BTK) protein inhibitor. It is co-developed and co-marketed by AbbVie company, Pharmacyclics, and Janssen Biotech. The post US FDA approves AbbVie-Janssen’s Imbruvica for cGVHD in children appeared first on Pharmaceutical Technology.